ReviewJournal of experimental & clinical cancer research : CR2019

Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

Fengzhi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.